Moss 14.08.19
Gentian Diagnostics AS announces its results for the second quarter and first half of 2019. The highlights include:
• 16 % growth in sales revenue in 2Q19 compared to 2Q18
• Total sales revenues of MNOK 10.2 in 2Q19, up from MNOK 8.8 in 2Q18
• FDA 510(k) clearance for the BÜHLMANN fCAL® turbo and with this access to the US market
• In July, Beckman Coulter, one of the top 5 global diagnostics companies, and Gentian have prolongated the trusted partnership agreement by another 6 years
• In August, Gentian announced the sales channel agreement for fCAL® turbo between Roche Diagnostics and Gentian’s sales partner Bühlmann Laboratories AG
Please find the report and results presentation enclosed. The documents will also be made available on www.gentian.no.
For further information, please contact:
Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525